CA2461248A1 - Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists - Google Patents
Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists Download PDFInfo
- Publication number
- CA2461248A1 CA2461248A1 CA 2461248 CA2461248A CA2461248A1 CA 2461248 A1 CA2461248 A1 CA 2461248A1 CA 2461248 CA2461248 CA 2461248 CA 2461248 A CA2461248 A CA 2461248A CA 2461248 A1 CA2461248 A1 CA 2461248A1
- Authority
- CA
- Canada
- Prior art keywords
- towards
- receptor
- compound
- dopamine
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000004031 partial agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 46
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 24
- 208000010877 cognitive disease Diseases 0.000 claims abstract 12
- 230000004770 neurodegeneration Effects 0.000 claims abstract 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 11
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 9
- 230000001225 therapeutic effect Effects 0.000 claims abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 claims 22
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 claims 22
- 102000005962 receptors Human genes 0.000 claims 22
- 108020003175 receptors Proteins 0.000 claims 22
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims 11
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 11
- 102000015554 Dopamine receptor Human genes 0.000 claims 11
- 108050004812 Dopamine receptor Proteins 0.000 claims 11
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 10
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 10
- 108010062431 Monoamine oxidase Proteins 0.000 claims 10
- 239000004480 active ingredient Substances 0.000 claims 10
- 229960004502 levodopa Drugs 0.000 claims 10
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 8
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 8
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 8
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 8
- 239000002207 metabolite Substances 0.000 claims 8
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 6
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 4
- 229960004851 pergolide Drugs 0.000 claims 4
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 4
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 claims 4
- 229960002776 pipamperone Drugs 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 claims 3
- 229960003678 selegiline hydrochloride Drugs 0.000 claims 3
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 2
- VGIGHGMPMUCLIQ-UHFFFAOYSA-N LSM-2183 Chemical compound C1=CC(F)=CC=C1N1CCN(CCCN2S(C=3C=CC=C4C=CC=C2C=34)(=O)=O)CC1 VGIGHGMPMUCLIQ-UHFFFAOYSA-N 0.000 claims 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 2
- 229960000911 benserazide Drugs 0.000 claims 2
- 229960002802 bromocriptine Drugs 0.000 claims 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 2
- 229960004596 cabergoline Drugs 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 229950002951 fananserin Drugs 0.000 claims 2
- 229960003980 galantamine Drugs 0.000 claims 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 2
- 229960003587 lisuride Drugs 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 229960003089 pramipexole Drugs 0.000 claims 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 2
- 229960001879 ropinirole Drugs 0.000 claims 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims 1
- OGJGQVFWEPNYSB-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-1H-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C3=CC=CN=C3NC=2)CC1 OGJGQVFWEPNYSB-UHFFFAOYSA-N 0.000 claims 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 1
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 claims 1
- ZFZPJDFBJFHYIV-UHFFFAOYSA-N 8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2C3=CC=CC=C3SN=2)C(=O)CC21CCCC2 ZFZPJDFBJFHYIV-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- NNAIYOXJNVGUOM-UHFFFAOYSA-N amperozide Chemical compound C1CN(C(=O)NCC)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 NNAIYOXJNVGUOM-UHFFFAOYSA-N 0.000 claims 1
- 229950000388 amperozide Drugs 0.000 claims 1
- 229960005245 asenapine Drugs 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229960003532 fluspirilene Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 229950010634 ocaperidone Drugs 0.000 claims 1
- -1 olanzepine Chemical compound 0.000 claims 1
- 229960001057 paliperidone Drugs 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 229950004554 tiospirone Drugs 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims 1
- 229960004496 zotepine Drugs 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 abstract 6
- 230000003042 antagnostic effect Effects 0.000 abstract 3
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 2
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract 2
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the use of compounds and compositions of compounds having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity in combination with other compounds for treating neurodegenerative diseases or disorders, such as Parkinson disease and related cognitive diseases or disorders. The invention also relates to pharmaceutical compositions for administration to a patient diagnosed as having a neurodegenerative disease or disorder and/or a cognitive disease or disorder, said pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compounds having 5-HT2A
antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound or compositions of said compounds in combination with another compound for treating said diseases or disorders to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said other compound.
antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound or compositions of said compounds in combination with another compound for treating said diseases or disorders to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said other compound.
Claims (40)
1. Use of a first compound for the preparation of a medicament for treating neurodegenerative diseases or disorders, characterized in that said compound is administered simultaneously with, separate from or prior to the administration of a second compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said second compound, further characterized in that said first compound has (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors.
2. Use according to claim 1, wherein said first compound is pipamperone.
3. Use according to claim 2, wherein said first compound is to be administered to a patient in a dose ranging between 5 and 15 mg of the active ingredient.
4. Use according to any of claims 1 to 3, wherein said neurodegenerative disease or disorder is Parkinson Disease.
5. Use according to any of claims 1 to 4, wherein said first compound is to be administered daily at least one day before administering said second compound.
6. Use according to any of claims 1 to 5, wherein said second compound is a dopamine receptor agonist.
7. Use according to claim 6, wherein said dopamine receptor agonist is chosen from the group consisting of amantadine, bromocriptine, cabergoline lisuride, pergolide, ropinirole and pramipexole, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
8. Use according to claim 7, wherein said dopamine receptor agonist is pergolide and is to be administered in a dose ranging between 0.5 and 10 mg of the active ingredient.
9. A pharmaceutical composition comprising (a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A
receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors and (b) a dopamine receptor agonist, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors and (b) a dopamine receptor agonist, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
10. Use according to any of claims 1 to 5, wherein said second compound is levodopa associated with a decarboxylase inhibitor.
11. Use according to claim 10, wherein said levodopa/decarboxylase-inhibitor is chosen from the group consisting of levodopa/carbidopa and levodopa/benserazide, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
12. Use according to claim 12, wherein said levodopa/decarboxylase-inhibitor is levodopa/carbidopa and is to be administered in a dose ranging between 2000 mg/ 200 mg and 100 mg/ 10 mg of the active ingredients.
13. A pharmaceutical composition comprising (a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A
receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and (b) a levodopa associated with a decarboxylase inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and (b) a levodopa associated with a decarboxylase inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
14. Use according to any of claims 1 to 5, wherein said second compound is a mono-amine oxidase B (MAO-B) inhibitor.
15. Use according to claim 14, wherein said second compound is selegilinehydrochloride or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
16. Use according to claim 15, wherein said selegilinehydrochloride is to be administered in a dose ranging between 2 and 25 mg of the active ingredient.
17. A pharmaceutical composition comprising (a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A
receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors and (b) a mono-amine oxidase B (MAO-B) inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors and (b) a mono-amine oxidase B (MAO-B) inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
18. Use of a composition for the preparation of a medicament for treating a neurodegenerative disease or disorder, characterized in that said composition is administered simultaneously with, separate from or prior to the administration of a third compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said third compound, further characterized in that said composition comprises a first compound having (i) a selective affinity for the D4 receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and a second compound having (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors.
19. Use according to claim 18, wherein said neurodegenerative disease or disorder is Parkinson Disease.
20. Use according to claim 18 or 19, wherein said first compound is chosen from the group consisting of, pipamperone, fananserin, L-745,870, PNU-1013876 and U-101387 or a pro-drug or a pharmaceutically acceptable salt thereof and wherein said second compound is chosen from the group comprising pipamperone, fananserin, ORG 5222, zotepine, olanzepine, clozapine, S16924, S18327, amperozide, serindole, MDL 100.907, tiospirone, fluspirilene, ocaperidone, risperidone, paliperidone and ziprasidone or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
21. Use according to any of claims 18 to 20, wherein said composition is to be administered to a patient in a dose ranging between 0.5 µg and 2000 mg for each of the active ingredients.
22. Use according to any of claims 18 to 20, wherein said third compound is a dopamine receptor agonist.
23. Use according to claim 22, wherein said dopamine receptor agonist is chosen from the group consisting of amantadine, bromocriptine, cabergoline lisuride, pergolide, ropinirole and pramipexole, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
24. Use according to claim 23, wherein said dopamine receptor agonist is pergolide and is to be administered in a dose ranging between 0.5 and 10 mg of the active ingredient.
25. A pharmaceutical composition comprising (a) a compound having a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, (b) a compound having a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT
receptors, and (c) a dopamine receptor agonist, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
receptors, and (c) a dopamine receptor agonist, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
26. Use according to any of claims 18 to 20, wherein said third compound is levodopa associated with a decarboxylase inhibitor.
27. Use according to claim 26 wherein said levodopa/decarboxylase-inhibitor is chosen from the group comprising levodopa/carbidopa, levodopa/benserazide, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
28. Use according to claim 27, wherein said levodopa/decarboxylase-inhibitor is levodopa/carbidopa and is to be administered in a dose ranging between 2000 mg/ 200 mg and 100 mg/ 10 mg of the active ingredients.
29. A pharmaceutical composition comprising (a) a compound having a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (b) a compound having a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT
receptors, and (c) levodopa associated with a decarboxylase inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
receptors, and (c) levodopa associated with a decarboxylase inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
30. Use according to any of claims 18 to 20, wherein said third compound is a mono-amine oxidase B (MAO-B) inhibitor.
31. Use according to claim 30, wherein said mono-amine oxidase B (MAO-B) inhibitor is selegelinehydrochloride or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
32. Use according to claim 31, wherein selegilinehydrochloride is to be administered in a dose ranging between 2 and 25 mg of the active ingredient.
33. A pharmaceutical composition comprising (a) a compound having a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (b) a compound having selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT
receptors. and (c) a mono-amine oxidase B (MAO-B) inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
receptors. and (c) a mono-amine oxidase B (MAO-B) inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a neurodegenerative disease or disorder such as Parkinson Disease.
34. Use of a compound as defined in any of claims 1 to 3, or of a composition as defined in claim 18, for the preparation of a medicament for treating a cognitive disease or disorder, characterized in that said compound or composition is administered simultaneously with, separate from or sequential to a cholinesterase inhibitor to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said cholinesterase inhibitor.
35. Use according to claim 34, wherein said disease or disorder is selected from the group consisting of delirium; dementia, such as Alzheimer Disease, substance-induced persisting dementia, vascular dementia, dementia due to a general medical condition chosen from the group comprising HIV disease, head trauma, Parkinson Disease, Huntington Disease, Pick Disease and Creutzfeldt-Jacob Disease; amnestic disorders due to a general medical condition or a substance-induced persisting amnestic disorder;
mild cognitive impairment disorder; and other cognitive disorders.
mild cognitive impairment disorder; and other cognitive disorders.
36. Use according to claim 34 or 35, wherein said cholinesterase inhibitor is chosen from the group consisting of donepezil, ENA-713, galantamine, memantine and tacrine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
37. Use according to claim 36, wherein said cholinesterase inhibitor is galantamine and is to be administered in a dose ranging between 5 and 50 mg of the active ingredient.
38. A pharmaceutical composition comprising (a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A
receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and (b) a cholinesterase inhibitor as a combined preparation for simultaneous, separate or sequential use for treating a cognitive disease or disorder.
receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and (b) a cholinesterase inhibitor as a combined preparation for simultaneous, separate or sequential use for treating a cognitive disease or disorder.
39. A pharmaceutical composition comprising (a) a compound having a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (b) a compound having a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT
receptors, and (c) a cholinesterase inhibitor , as a combined preparation for simultaneous, separate or sequential use for treating a cognitive disease or disorder.
receptors, and (c) a cholinesterase inhibitor , as a combined preparation for simultaneous, separate or sequential use for treating a cognitive disease or disorder.
40. A pharmaceutical composition according to any of claims 9, 13, 17 or 38 wherein said compound having (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT
receptors, is pipamperone and is present in the composition in a dose ranging between 5 and 15 mg of active ingredient, expressed as the daily dose to be administered to a patient in need thereof.
receptors, is pipamperone and is present in the composition in a dose ranging between 5 and 15 mg of active ingredient, expressed as the daily dose to be administered to a patient in need thereof.
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2461248 CA2461248C (en) | 2003-12-02 | 2004-03-18 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| CA 2487529 CA2487529A1 (en) | 2003-12-02 | 2004-11-15 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| EP10159625A EP2272514A1 (en) | 2003-12-02 | 2004-12-02 | Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases |
| PT04801138T PT1708790E (en) | 2003-12-02 | 2004-12-02 | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
| DE602004026781T DE602004026781D1 (en) | 2003-12-02 | 2004-12-02 | USE OF PIPAMPERONE AND A D2 RECEPTOR ANTAGONIST OR A SEROTONINE / DOPAMINE ANTAGONIST |
| PCT/BE2004/000172 WO2005053796A1 (en) | 2003-12-02 | 2004-12-02 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| ES04801138T ES2343962T3 (en) | 2003-12-02 | 2004-12-02 | USE OF PIPAMPERONE AND A D2 RECEIVER ANTAGONIST OR A SEROTONINE / DOPAMINE ANTAGONIST FOR THE TREATMENT OF PSYCHOTIC DISORDERS. |
| EP04801138A EP1708790B1 (en) | 2003-12-02 | 2004-12-02 | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
| HR20100376T HRP20100376T1 (en) | 2003-12-02 | 2004-12-02 | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
| JP2006541759A JP4571645B2 (en) | 2003-12-02 | 2004-12-02 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| SI200431439T SI1708790T1 (en) | 2003-12-02 | 2004-12-02 | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
| DK04801138.1T DK1708790T3 (en) | 2003-12-02 | 2004-12-02 | Use of pipamperone by a D2 receptor antagonist or serotonin / dopamine antagonist in the treatment of psychotic disorders |
| AT04801138T ATE464901T1 (en) | 2003-12-02 | 2004-12-02 | USE OF PIPAMPERONE AND A D2 RECEPTOR ANTAGONIST OR A SEROTONIN/DOPAMINE ANTAGONIST FOR THE TREATMENT OF PSYCHOTIC DISORDERS |
| US10/580,962 US8304431B2 (en) | 2003-12-02 | 2004-12-02 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| RSP-2010/0323A RS51331B (en) | 2003-12-02 | 2004-12-02 | USE OF PIPAMPERON AND D2-RECEPTOR ANTAGONISTS OR SEROTONIN / DOPAMINE ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS |
| CA002547639A CA2547639A1 (en) | 2003-12-02 | 2004-12-02 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| PL04801138T PL1708790T3 (en) | 2003-12-02 | 2004-12-02 | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
| CY20101100611T CY1111017T1 (en) | 2003-12-02 | 2010-07-05 | USE OF PIPAMERONIS AND A D-2 COMPETITOR OR SEROTONIN / DOPAMIN COMPONENT OR COMPETITOR FOR THE TREATMENT OF PSYCHOLOGICAL DISORDERS |
| US12/924,615 US20110136865A1 (en) | 2003-12-02 | 2010-09-30 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US13/065,638 US20110207776A1 (en) | 2003-12-02 | 2011-03-25 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2,451,798 | 2003-12-02 | ||
| CA2451798A CA2451798C (en) | 2003-12-02 | 2003-12-02 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| EP04447001.1 | 2004-01-05 | ||
| EP04447001 | 2004-01-05 | ||
| CA 2461248 CA2461248C (en) | 2003-12-02 | 2004-03-18 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2461248A1 true CA2461248A1 (en) | 2005-06-02 |
| CA2461248C CA2461248C (en) | 2009-12-22 |
Family
ID=34623380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2461248 Expired - Fee Related CA2461248C (en) | 2003-12-02 | 2004-03-18 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2461248C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855195B2 (en) | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US7884096B2 (en) | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US8304431B2 (en) | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| WO2021140103A1 (en) * | 2020-01-06 | 2021-07-15 | Anima | Cognitive disorder prevention and therapy |
-
2004
- 2004-03-18 CA CA 2461248 patent/CA2461248C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855195B2 (en) | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US7884096B2 (en) | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US8304431B2 (en) | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| WO2021140103A1 (en) * | 2020-01-06 | 2021-07-15 | Anima | Cognitive disorder prevention and therapy |
| WO2021139874A1 (en) * | 2020-01-06 | 2021-07-15 | Anima | Cognitive disorder prevention and therapy |
| CN115279356A (en) * | 2020-01-06 | 2022-11-01 | 安尤罗泰克Ip私人有限公司 | Cognitive Impairment Prevention and Treatment |
| AU2021206771B2 (en) * | 2020-01-06 | 2025-03-06 | Aneurotech Bv | Cognitive disorder prevention and therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2461248C (en) | 2009-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009514929A (en) | Use of flibanserin for the treatment of premenopausal sexual desire disorders | |
| UA72783C2 (en) | Agonist of central canabinoid receptors for preparation of drug disaccustoming smoking, combined pharmaceutical composition and kit | |
| HU229353B1 (en) | Improved transdermal therapeutic system for treatment of parkinson's disese | |
| JP2009513713A5 (en) | ||
| JPWO1996009069A1 (en) | New medical uses of 5HT ▲lower 3▼ antagonists | |
| JP2005505539A (en) | Composition comprising a CB1 receptor antagonist for the treatment of Parkinson's disease and a product that activates brain dopaminergic neurotransmission | |
| CA2450787C (en) | Active ingredient combination for pharmacological addictive substance or intoxicant therapy | |
| JP2002520362A5 (en) | ||
| WO2004096118B1 (en) | Composition for improving cognition and memory | |
| MX2009002311A (en) | Pharmaceutical compositions for the treatment of fungal infections. | |
| JP2016505050A5 (en) | ||
| CA2461248A1 (en) | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists | |
| JP2019502734A (en) | Treatment of hand eczema | |
| MX2007012300A (en) | Therapeutic use of nefopam and analogues thereof. | |
| JP2004535463A (en) | Combined therapy for treatment of heart failure | |
| CZ2004524A3 (en) | Agonists of nicotine acetylcholine receptor useful for the treatment of restless legs | |
| CA2228813A1 (en) | Medicament for inhibiting dependency and tolerance developed by narcoticanalgesic agent | |
| CZ2004739A3 (en) | Use of desoxypeganine for treating clinical depression | |
| JP2002504134A (en) | Use of a dolafradine analog to treat pain | |
| JPH0564124B2 (en) | ||
| TW201841635A (en) | Composition and method for treating depression | |
| CA2552759A1 (en) | Combination of organic compounds | |
| KR20000029647A (en) | Method for treating bipolar disorder | |
| JPWO1999008675A1 (en) | Treatment for irritable bowel syndrome | |
| KR101086895B1 (en) | Pharmaceutical composition comprising sibutramine and thioctic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140318 |